6533b7dbfe1ef96bd12701e0
RESEARCH PRODUCT
Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis
Michael WangJose Angel Hernandez-rivasAndre GoyLori ParisiSimon RuleKeqin QiGeorg HessRebecca AuerSanjay DeshpandeMartin DreylingBrad S. Kahlsubject
Oncologymedicine.medical_specialtySalvage therapyDrug resistanceLymphoma Mantle-Cellchemistry.chemical_compoundText miningPiperidinesInternal medicinemedicineHumansOnline Only ArticlesSurvival rateSalvage TherapyClinical Trials as Topicbusiness.industryAdenineHematologymedicine.diseasePrognosisLymphomaSurvival RatePyrimidineschemistryDrug Resistance NeoplasmIbrutinibRelapsed refractoryPyrazolesMantle cell lymphomaNeoplasm Recurrence LocalbusinessFollow-Up Studiesyear | journal | country | edition | language |
---|---|---|---|---|
2019-05-01 |